Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA226662 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Comparison between Estrogen receptor positive and Estrogen receptor negative breast cancer samples
| PRJNA107971 | ENA
Project description:GPR30-mediated estrogen signaling in Estrogen Receptor alpha and beta negative SKBR3 breast cancer cells
| PRJNA106185 | ENA
Project description:Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer
| PRJNA302603 | ENA
Project description:Purpose: To characterize the expression of phosphatases in estrogen receptor negative breast cancer Little is known about the role of phosphatases in the major estrogen receptor negative breast cancer phenotypes (i.e. those overexpressing ERBB2 and the triple negative). We carried out microarray phosphatome profiling in 41 estrogen receptor negative (ER-) breast cancer patients (as determined by immunohistochemistry (IHC)) containing both ERBB2+ and ERBB2- in order to characterize the differences between these groups by Statistical Analysis of Microarrays (SAM). Our findings point to the importance of the MAPK and PI3K pathways in ER- BCs as some of the most differentially expressed phosphatases (like DUSP4 and DUSP6) share ERK as substrate, or regulate the PI3K pathway (INPP4B, PTEN). These observations are also confirmed by pathway and GSEA analysis. It is shown that both ER- ERBB2+ and triple negative breast cancers have a distinctive pattern of phosphatase RNA expression. Surgical specimens from primary breast cancers that were estrogen receptor negative according to immunohistochemistry
2014-06-30 | E-GEOD-51999 | biostudies-arrayexpress
Project description:Comparison between Estrogen receptor positive and Estrogen receptor negative breast cancer samples Keywords: breast cancer type comparison
2008-09-17 | GSE10510 | GEO
Project description:Effects of retinoids on estrogen-receptor-positive and -negative breast carcinoma cells: mRNA profiling
| PRJNA123773 | ENA
Project description:HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and positive breast cancer
| PRJNA120039 | ENA
Project description:Micro RNA (miRNA) profiling of breast cancer subtype was demonstrated using RT-PCR. We present herein two cases with miRNA profiling in estrogen receptor (ER)-positive and -negative breast cancer. The level of miR-181a expression in ER-positive cancer was higher than in ER-negative cancer, while expression of miR-27a, -107 and -195 was lower in ER-positive when compared with ER-negative cancer.
2018-10-13 | GSE121172 | GEO
Project description:Estrogen receptor positive MCF-7 and estrogen receptor negative MDA-MB-231 breast cancer cells treated with 10µg/ml phytoestrogen Emodin (1,3,8-trihydroxy-6-methylanthraquinone) and their control cells (untreated with Emodin) were incubated for 48 hours. All samples were prepared as duplicates to have biological replicates. Isolated RNA samples were used for miRNA microarray analysis. Through this experiment miRNA profiling of breast cancer cells having estrogen receptor and not were revealed upon phytoestrogen Emodin treatment.
2023-11-30 | E-MTAB-10170 | biostudies-arrayexpress
Project description:Gene expression profiling of invasive breast cancer events from the tamoxifen prevention trial validates low estrogen receptor mRNA level as the main determinant of tamoxifen resistance in estrogen receptor positive breast cancer. In NSABP Breast Cancer Prevention Trial (BCPT), tamoxifen reduced the incidence of estrogen receptor (ER) positive tumors but not estrogen receptor negative breast cancer. More importantly, only 69% of estrogen receptor positive tumors were prevented by tamoxifen. The ER positive tumors arising in tamoxifen arm provides an ideal clinical model for acquired tamoxifen resistance. Based on data from NSABP trial B14 which showed linear prediction of the degree of benefit from adjuvant tamoxifen by the levels of ESR1 mRNA coding for ER-alpha, we hypothesized a priori that level of ESR1 mRNA would be lower in ER positive tumors arising in tamoxifen arm compared to those in placebo arm of BCPT. Keywords: Gene expression profiling analysis
2011-12-08 | GSE12665 | GEO